Mission Statement
R&D Pipeline

PEG Biosciences is proud of working with our strategic partners to ensure the best expertise is applied to our technologies and drug development.

Rutgers Brain Health Institute (BHI) and Rutgers Endocrine Research

The BHI is an interdisciplinary institute at Rutgers University, and has outstanding strength and a broad range of research interests in the area of neurodegeneration, motivational & affective neuroscience, cognitive & sensory neuroscience, and neurodevelopment. PEG Biosciences works with BHI and Endocrine Research to develop medicines for the treatment of disease-related neuroscience, including pain, opioids and alcohol addictions, neuro disorders and neurodegenerative diseases.

Kelun Pharmaceutical

PEG Biosciences collaborates with Kelun Pharmaceutical to develop innovative biotherapeutics targeted to unmet medical needs in the areas of oncology and infectious disease based on our proprietary BioSynersys™ platform technology.

Kelun Pharmaceutical is a leading biotechnology and pharmaceutical company in China. Kelun Group is a 2015 Fortune 500 company in China and has 30,000 employees in more than 90 subsidiaries with 2015 revenues exceeding USD $6 billion. Kelun offers over 520 products and is the market leader of injectable and infusion technologies.

Rutgers Cancer Institute of New Jersey (CINJ)

Rutgers Cancer Institute of New Jersey is the National Cancer Institute-designated Comprehensive Cancer Center and is recognized as one of the nation’s premier research and clinical cancer treatment centers.  PEG Biosciences works with CINJ in the area of immuno-oncology to transform research into clinical medicine.